Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment

Elisa ten Hacken, PhD, Mariela Sivina, PhD, Li Ping, PhD, Susan O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael J. Keating, MD, Cristina Scielzo, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD PhD

Blood (2015) 126 (23): 2915.

https://doi.org/10.1182/blood.V126.23.2915.2915

Published: 2015

Journal Articles

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Michael Steurer, MD, Marco Montillo, MD, Lydia Scarfò, Francesca Romana Mauro, Johannes Andel, MD, Sophie Wildner, MD, Livio Trentin, MD, Ann Janssens, MD, Sonja Burgstaller, MD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 1996.

https://doi.org/10.1182/blood.V124.21.1996.1996

Published: 2014

Journal Articles

Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome

Elisa ten Hacken, PhD, Cristina Scielzo, PhD, Susan O'Brien, MD, William G. Wierda, MD PhD, Michael Keating, MBBS, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD PhD

Blood (2014) 124 (21): 3312.

https://doi.org/10.1182/blood.V124.21.3312.3312

Published: 2014

Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 3331.

https://doi.org/10.1182/blood.V124.21.3331.3331

Published: 2014

Journal Articles

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Andrés J.M. Ferreri, Giovanni Donadoni, MD, Maria Giuseppina Cabras, MD, Caterina Patti, MD, Michael Mian, Renato Zambello, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Alfonso D'Arco, Gianluca Doa, Marta Bruno-Ventre, Marco Foppoli, MD, Alessandro Fanni, MD, Antonino Mulè, MD, Fabio Ciceri, MD, Federico Caligaris-Cappio, MD

Blood (2014) 124 (21): 1724.

https://doi.org/10.1182/blood.V124.21.1724.1724

Published: 2014

Journal Articles

Anergy in CLL: Moving Towards the Clinic

Benedetta Apollonio, Tania Veliz Rodriguez, Cristina Scielzo, PhD, Maria Teresa Sabrina Bertilaccio, Lydia Scarfò, Federico Caligaris-Cappio, MD, Paolo Ghia, MD PhD

Blood (2014) 124 (21): 4677.

https://doi.org/10.1182/blood.V124.21.4677.4677

Published: 2014

Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Marco Gobbi, MD, Michael Steurer, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Ann Janssens, MD, Livio Trentin, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD

Blood (2013) 122 (21): 1635.

https://doi.org/10.1182/blood.V122.21.1635.1635

Published: 2013

Journal Articles

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Marta Bruno Ventre, MD, Marco Foppoli, MD, Giovanni Citterio, MD, Giovanni Donadoni, MD, Maurilio Ponzoni, MD, Silvia Govi, MD, Lydia Scarfò, MD, Marianna Sassone, MD, Federico Caligaris -Cappio, MD, Prof., Andres J.M. Ferreri, MD, PhD

Blood (2013) 122 (21): 4365.

https://doi.org/10.1182/blood.V122.21.4365.4365

Published: 2013

Journal Articles

Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo

Maria Teresa Sabrina Bertilaccio, Sarah Tettamanti, PhD, Greta Maria Paola Giordano Attianese, PhD, Giovanni Galletti, Silvia Arcangeli, Tania Veliz Rodriguez, Chiara Francesca Magnani, PhD, Federica Barbaglio, Lydia Scarfò, MD, Maurilio Ponzoni, MD, Andrea Biondi, MD, Federico Caligaris-Cappio, MD, Ettore Biagi, MD, PhD, Paolo Ghia, MD, PhD

Blood (2013) 122 (21): 4171.

https://doi.org/10.1182/blood.V122.21.4171.4171

Published: 2013

Journal Articles

Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia

Elisa ten Hacken, Cristina Scielzo, William G. Wierda, MD, PhD, Michael J. Keating, MD, Susan O'Brien, MD, Paolo Ghia, MD, PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 4143.

https://doi.org/10.1182/blood.V122.21.4143.4143

Published: 2013

Journal Articles

Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

Marco Gobbi, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Stephanie Vauléon, PhD, Stefan Zöllner, PhD, Thomas Dümmler, PhD, Anna Kruschinski, PhD, Frank Fliegert, MD

Blood (2012) 120 (21): 4593.

https://doi.org/10.1182/blood.V120.21.4593.4593

Published: 2012

Journal Articles

Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL

Cristina Maccalli, Maria Gounari, Kostas Stamatopoulos, Federico Caligaris-Cappio, MD, Giorgio Parmiani, Paolo Ghia

Blood (2012) 120 (21): 1775.

https://doi.org/10.1182/blood.V120.21.1775.1775

Published: 2012

Journal Articles

Targeting B Cell Anergy in Chronic Lymphocytic Leukemia

Benedetta Apollonio, Cristina Scielzo, Maria Teresa Sabrina Bertilaccio, Elisa ten Hacken, Lydia Scarfò, Paolo Ghia, Marta Muzio, Federico Caligaris-Cappio, MD

Blood (2012) 120 (21): 3863.

https://doi.org/10.1182/blood.V120.21.3863.3863

Published: 2012

Journal Articles

Targeting the LYN/HS1 Signaling Axis in Chronic Lymphocytic Leukemia

Elisa ten Hacken, Cristina Scielzo, Maria Teresa Sabrina Betilaccio, Lydia Scarfò, MD, Benedetta Apollonio, Maurilio Ponzoni, Kostas Stamatopoulos, Paolo Ghia, Federico Caligaris-Cappio, MD

Blood (2012) 120 (21): 928.

https://doi.org/10.1182/blood.V120.21.928.928

Published: 2012

Journal Articles

The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma

Francesca Cottini, Teru Hideshima, MD, PhD, Martin Sattler, PhD, Federico Caligaris-Cappio, MD, Kenneth C. Anderson, MD, Giovanni Tonon, MD PhD

Blood (2012) 120 (21): 725.

https://doi.org/10.1182/blood.V120.21.725.725

Published: 2012

Journal Articles

CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL

Paolo Ghia, MD, PhD, Claudia Fazi, PhD, Lorenza Pecciarini, PhD, Lydia Scarfò, MD, Francesca Cottini, MD, Antonis Dagklis, PhD, Agnieszka Janus, MD, Cristina Scielzo, Cinzia Sala, PhD, Daniela Toniolo, PhD, Federico Caligaris-Cappio, MD

Blood (2010) 116 (21): 2440.

https://doi.org/10.1182/blood.V116.21.2440.2440

Published: 2010

Journal Articles

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Blood (2009) 114 (22): 535.

https://doi.org/10.1182/blood.V114.22.535.535

Published: 2009

Journal Articles

The Immunoglobulin Gene Repertoire of Low-Count CLL-Like MBL Is Different from CLL: Diagnostic Considerations and Implications for Clinical Monitoring

Antonis Dagklis, Claudia Fazi, Cinzia Sala, Valeria Cantarelli, Cristina Scielzo, Roberto Massacane, MD, Daniela Toniolo, Federico Caligaris-Cappio, MD, Kostas Stamatopoulos, MD, Paolo Ghia, MD, PhD

Blood (2008) 112 (11): 779.

https://doi.org/10.1182/blood.V112.11.779.779

Published: 2008

Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Blood (2008) 112 (11): 325.

https://doi.org/10.1182/blood.V112.11.325.325

Published: 2008

Journal Articles

A Molecular Signature of Anergy Detected in a Subset of CLL Patients.

Paolo Ghia, MD, PhD, Marta Muzio, PhD, Benedetta Apollonio, Cristina Scielzo, Michela Frenquelli, Irene Vandoni, MD, Vassiliki Boussiotis, MD, PhD, Federico Caligaris-Cappio, MD

Blood (2007) 110 (11): 742.

https://doi.org/10.1182/blood.V110.11.742.742

Published: 2007

NARROW

IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Anergy in CLL: Moving Towards the Clinic

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo

Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia

Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL

Targeting B Cell Anergy in Chronic Lymphocytic Leukemia

Targeting the LYN/HS1 Signaling Axis in Chronic Lymphocytic Leukemia

The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma

CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL

The Immunoglobulin Gene Repertoire of Low-Count CLL-Like MBL Is Different from CLL: Diagnostic Considerations and Implications for Clinical Monitoring

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

A Molecular Signature of Anergy Detected in a Subset of CLL Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only